The abstract is read at the publisher; the summary is JClub's.
Across 24 US Food and Drug Administration (neo)adjuvant solid-tumor approvals (2010–2023), only 4 of 11 trials with overall survival data showed an overall survival benefit at approval or publication.
- Why it matters: (Neo)adjuvant systemic treatments are intended to reduce recurrence risk, but surrogate endpoints, censoring, and incomplete reporting can obscure whether benefits and harms align with patient priorities.
- What they did: The authors reviewed FDA (neo)adjuvant approvals for solid tumors from 2010–2023 with time-to-event endpoints, descriptively assessing trial design, endpoints, censoring, and whether sample size and event expectations were reproducible.
- The result: They found 52% (11 of 21) showed overall survival benefit at any time, while 79% reported quality-of-life outcomes and 31% reported clinically meaningful declines in one or more domains.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.